|
Intellectual Property VGX Pharmaceuticals, Inc. has built itself on a foundation of broad, innovative research and development in the biopharmaceutical arena. VGX has separated itself from other biopharmaceutical companies with its comprehensive and extensive proprietary technologies. These technologies are protected by an expansive array of intellectual property rights including trade secrets, copyrights, trademarks, and patents. Furthermore, VGX is a global biopharmaceutical company with intellectual property rights established in the United States and abroad, including extensive rights in Asia where its affiliate, VGX International operates. VGX's patent rights are comprehensive in all the areas in which it operates, including pharmaceuticals, biopharmaceuticals, vaccines, gene delivery, animal health therapies, and cGMP manufacturing. Current therapeutic technologies covered by VGX patents include: anti-viral, anti-inflammatory, and anti-cancer compounds; GHRH-related gene therapy; DNA Vaccines for cancer and infectious diseases including HIV, influenza, and HPV; and DNA delivery devices. VGX is well recognized in the industry for its significant technical advances. It has also gained high regard for its level of skill and service in contract manufacturing and research partnerships. VGX’s strong reputation has generated substantial goodwill, which has been partially captured in its various trademarks including VGX™, CELLECTRA™, LifeTide™, PENNVAX™-B, PICTOVIR™, and SynCon™. |